1st Quarter - Amendment

BRISTOL-MYERS SQUIBB COMPANY for BRISTOL-MYERS SQUIBB COMPANY

Firm
Client
Income
—
Expenses
$730,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report Apr 20, 2021 $730,000 Replaced
1st Quarter - Amendment (this page) Feb 7, 2022 $730,000 Yes

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Intellectual Property Reform concerning bio-pharmaceutical industry. No related bill number Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number.

LobbyistCovered position, as disclosed
THOMAS BRUNET —
JOHN DEOUDES —
KATHRYN NOVARIA New —
LANE PENRY —
RICARDO SANCHEZ ORTEGON —
PAUL ANTHONY WILLIAMS —

Contacted: HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); SENATE; Commerce, Dept of (DOC)

Taxation/Internal Revenue Code TAX

Proposed policies regarding corporate tax reform regarding all bio-pharmaceutical related provisions. No bill number Import Taxes regarding all bio-pharmaceutical related provisions. No bill number.

LobbyistCovered position, as disclosed
JOHN DEOUDES —
LANE PENRY —
PAUL ANTHONY WILLIAMS —

Contacted: U.S. Trade Representative (USTR); Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS); SENATE; Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Essential Medicines/Buy American regarding all bio-pharmaceutical related provisions. No bill number. Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number.

LobbyistCovered position, as disclosed
THOMAS BRUNET —
JOHN DEOUDES —
KATHRYN NOVARIA —
LANE PENRY —
RICARDO SANCHEZ ORTEGON —
PAUL ANTHONY WILLIAMS —

Contacted: Commerce, Dept of (DOC); SENATE; U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA)

Health Issues HCR

HR 1319 - American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S.464 - Safe Step Act - regarding all bio-pharmaceutical related provisions H.R. 2163 To amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for an medication step therapy protocol, and for other purposes -regarding all bio-pharmaceutical related provisions. H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes - regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation - regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D - regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan - regarding all bio-pharmaceutical related provisions. Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number.

LobbyistCovered position, as disclosed
THOMAS BRUNET —
JOHN DEOUDES —
KATHRYN NOVARIA —
LANE PENRY —
RICARDO SANCHEZ ORTEGON —
PAUL ANTHONY WILLIAMS —

Contacted: U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); SENATE; Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC)

Bills named: H.R. 2163 (117th), H.R. 2071 (117th), H.R. 1319 (117th), S. 464 (117th), S. 908 (117th), H.R. 2139 (117th)

Medicare/Medicaid MMM

H.R. 2163 To amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for an medication step therapy protocol, and for other purposes regarding all bio-pharmaceutical related provisions. H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan regarding all bio-pharmaceutical related provisions. Cancer Drug Parity Act/Oral Parity regarding all bio-pharmaceutical related provisions. No bill number. Issues related to the 340B Drug Pricing Program regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number.

LobbyistCovered position, as disclosed
THOMAS BRUNET —
JOHN DEOUDES —
KATHRYN NOVARIA —
LANE PENRY —
RICARDO SANCHEZ ORTEGON —
PAUL ANTHONY WILLIAMS —

Contacted: U.S. Trade Representative (USTR); Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); SENATE; Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 908 (117th), H.R. 2163 (117th), H.R. 2071 (117th), H.R. 2139 (117th), H.R. 1319 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.